Gilead, Viking and Biohaven detail promising preclinical research in obesity and NASH

In a twist, preclinical research in metabolic disease is peaking more investor interest at the American Diabetes Association’s annual meeting than in past years. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SpA Patients Do Just Fine Managing Their Own Follow-Up Care

VIENNA — Patients with axial spondyloarthritis (axSpA) who initiated follow-up contacts with their clinicians fared no worse medically than those monitored remotely or, as is

June 17, 2024

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder | Psychedelic Invest

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not

September 26, 2023

PhRMA renews pharmacy benefits manager campaign as Congressional scrutiny heats up

Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts. Sumitomo Pharma

May 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.